Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma

Pacini, Simone; Montali, Marina; Mazziotta, Francesco; Schifone, Claudia Pia; Macchia, Lucia; Carnicelli, Vittoria; Panvini, Francesca M.; Barachini, Serena; Notarfranchi, Laura; Previti, Giovanni Battista; Buda, Gabriele; Petrini, Mario

doi:10.18632/oncotarget.27285

Cited by 3 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have shown, in human liposarcoma and melanoma, the presence of alterations in specific tumor ECs: a heterogeneous population probably trans-differentiated from VSCs [ 105 ]. Our research group also identified specific MPCs in multiple myeloma (MM), demonstrating their involvement in both tumor growth and osteolysis [ 106 ]. These MPCs contributed to the formation of new blood vessels and reduced osteoblastogenesis.…”

Section: Vascular Progenitor Cells In Cancersmentioning

confidence: 99%

Vascular Progenitor Cells: From Cancer to Tissue Repair

Barachini

Ghelardoni

Madonna

2023

JCM

Self Cite

View full text Add to dashboard Cite

Vascular progenitor cells are activated to repair and form a neointima following vascular damage such as hypertension, atherosclerosis, diabetes, trauma, hypoxia, primary cancerous lesions and metastases as well as catheter interventions. They play a key role not only in the resolution of the vascular lesion but also in the adult neovascularization and angiogenesis sprouting (i.e., the growth of new capillaries from pre-existing ones), often associated with carcinogenesis, favoring the formation of metastases, survival and progression of tumors. In this review, we discuss the biology, cellular plasticity and pathophysiology of different vascular progenitor cells, including their origins (sources), stimuli and activated pathways that induce differentiation, isolation and characterization. We focus on their role in tumor-induced vascular injury and discuss their implications in promoting tumor angiogenesis during cancer proliferation and migration.

show abstract

Section: Vascular Progenitor Cells In Cancersmentioning

confidence: 99%

Vascular Progenitor Cells: From Cancer to Tissue Repair

Barachini

Ghelardoni

Madonna

2023

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…They reportedly play an immunomodulatory role in tumor microenvironment, also contributing to local tumor aggressiveness in some hematological malignancies. [89][90][91] Due to their anti-inflammatory effects and their interaction with macrophages, many trials use MSC to treat aggressive GVHD, 92 but in some cases MSCs were also enginereed Open access to hyperexpress cytokines as IFN-γ and inoculated within tumor tissue. 93 The administration of systemic thirdparty MSC in patients with steroid refractory acute and chronic GVHD showed response rates up to 70%.…”

Section: Cellular Immunotherapy For Covid-19mentioning

confidence: 99%

Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy

Iovino

Hill

Gnjatic

et al. 2021

J Immunother Cancer

View full text Add to dashboard Cite

COVID-19, the syndrome caused by the infection with SARS-CoV-2 coronavirus, is characterized, in its severe form, by interstitial diffuse pneumonitis and acute respiratory distress syndrome (ARDS). ARDS and systemic manifestations of COVID-19 are mainly due to an exaggerated immune response triggered by the viral infection. Cytokine release syndrome (CRS), an inflammatory syndrome characterized by elevated levels of circulating cytokines, and endothelial dysfunction are systemic manifestations of COVID-19. CRS is also an adverse event of immunotherapy (IMTX), the treatment of diseases using drugs, cells, and antibodies to stimulate or suppress the immune system. Graft-versus-host disease complications after an allogeneic stem cell transplant, toxicity after the infusion of chimeric antigen receptor-T cell therapy and monoclonal antibodies can all lead to CRS. It is hypothesized that anti-inflammatory drugs used for treatment of CRS in IMTX may be useful in reducing the mortality in COVID-19, whereas IMTX itself may help in ameliorating effects of SARS-CoV-2 infection. In this paper, we focused on the potential shared mechanisms and differences between COVID-19 and IMTX-related toxicities. We performed a systematic review of the clinical trials testing anti-inflammatory therapies and of the data published from prospective trials. Preliminary evidence suggests there might be a benefit in targeting the cytokines involved in the pathogenesis of COVID-19, especially by inhibiting the interleukin-6 pathway. Many other approaches based on novel drugs and cell therapies are currently under investigation and may lead to a reduction in hospitalization and mortality due to COVID-19.

show abstract

Hypoxia Promotes the Stemness of Mesangiogenic Progenitor Cells and Prevents Osteogenic but not Angiogenic Differentiation

Burzi,

Parchi,

Barachini

et al. 2024

Stem Cell Rev and Rep

View full text Add to dashboard Cite

The stem cell niche in the bone marrow is a hypoxic environment, where the low oxygen tension preserves the pluripotency of stem cells. We have identified mesangiogenic progenitor cells (MPC) exhibiting angiogenic and mesenchymal differentiation capabilities in vitro. The effect of hypoxia on MPC has not been previously explored. In this study, MPCs were isolated from volunteers' bone marrow and cultured under both normoxic and hypoxic conditions (3% O2). MPCs maintained their characteristic morphology and surface marker expression (CD18 + CD31 + CD90-CD73-) under hypoxia. However, hypoxic conditions led to reduced MPC proliferation in primary cultures and hindered their differentiation into mesenchymal stem cells (MSCs) upon exposure to differentiative medium. First passage MSCs derived from MPC appeared unaffected by hypoxia, exhibiting no discernible differences in proliferative potential or cell cycle. However, hypoxia impeded the subsequent osteogenic differentiation of MSCs, as evidenced by decreased hydroxyapatite deposition. Conversely, hypoxia did not impact the angiogenic differentiation potential of MPCs, as demonstrated by spheroid-based assays revealing comparable angiogenic sprouting and tube-like formation capabilities under both hypoxic and normoxic conditions. These findings indicate that hypoxia preserves the stemness phenotype of MPCs, inhibits their differentiation into MSCs, and hampers their osteogenic maturation while leaving their angiogenic potential unaffected. Our study sheds light on the intricate effects of hypoxia on bone marrow-derived MPCs and their differentiation pathways. Graphical Abstract

show abstract

Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma

Cited by 3 publications

References 36 publications

Vascular Progenitor Cells: From Cancer to Tissue Repair

Vascular Progenitor Cells: From Cancer to Tissue Repair

Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy

Hypoxia Promotes the Stemness of Mesangiogenic Progenitor Cells and Prevents Osteogenic but not Angiogenic Differentiation

Contact Info

Product

Resources

About